Efgartigimod Expanded Access for Generalized Myasthenia Gravis

• ClinicalTrials.gov Identifier: NCT04777734
• Expanded Access Status: Approved for marketing
• First Posted: March 2, 2021
• Last Update Posted: April 29, 2022
• Sponsor: argenx
• Information provided by (Responsible Party): argenx

Study Description

Brief Summary:

This expanded access protocol applies to patients with gMG who are not enrolled in an ongoing clinical trial. The aim of the trial is to provide patients with generalized myasthenia gravis (gMG), who are ineligible to participate in a clinical trial, access to efgartigimod treatment before regulatory approval.

There are country-specific protocols and also individual use EAP. Recruitment for the treatment protocol in US is now closed (ARGX-113-EAP-2101).

Condition or disease	Intervention/treatment
Generalized Myasthenia Gravis	Biological: efgartigimod

Study Design

• Study Type: Expanded Access
• Expanded Access Type: Treatment IND/Protocol

See clinical trials of the intervention/treatment in this expanded access record.

• Official Title: An Expanded Access Program for Efgartigimod Treatment in Patients With Generalized Myasthenia Gravis

Interventions

Intervention Details:

• Biological: efgartigimod
  an intravenous infusion of efgartigimod
  Other Name: ARGX-113

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All

Criteria

Inclusion Criteria:

• Patient is ≥18 years of age, at the time of signing the informed consent
• Patient has a diagnosis of MG (AChR-Ab seropositive or seronegative) with generalized muscle weakness
• Patient has been vaccinated against COVID-19 or has had a negative COVID-19 test result in the 2 weeks before enrollment
• Patient has documented IgG >6 g/L within one month of screening

• Patient agrees to contraceptive use consistent with local regulations and scientific rationale regarding the methods of contraception and:

  1. Male patients: must agree to use an acceptable method of contraception and to not donate sperm from the time of providing informed consent until the end of the program
  2. Female patients: Women of childbearing potential must use a highly effective or acceptable method of contraception and have a negative serum pregnancy test at screening
• Patient provides signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and this protocol
• Patients with a history of hepatitis B, hepatitis C, or HIV must have a documented negative test for an active viral infection.

Exclusion Criteria:

• Patient has clinically significant uncontrolled active or chronic bacterial, viral, or fungal infection at screening
• Patient has a known autoimmune disease that, in the opinion of the treating physician, would interfere with an accurate assessment of clinical symptoms of gMG or put the patient at undue risk
• Patient has a history of malignancy unless it is deemed to be cured by adequate treatment with no evidence of recurrence for ≥3 years before the first administration of the IMP. Patients with documentation of adequate treatment of the following cancers can be included at any time: basal cell or squamous cell skin cancer; carcinoma in situ of the cervix; carcinoma in situ of the breast; incidental histological finding of prostate cancer (TNM stage T1a or T1b)
• Patient has clinical evidence of other significant serious diseases, has recently had major surgery, or has any other condition that, in the opinion of the treating physician, could put the patient at undue risk
• Patient may be excluded based upon review of clinical medical records and screening clinical safety laboratory test results
• Patient has received a live or a live-attenuated vaccination during the month before screening
• Patient is pregnant and/or lactating or intends to become pregnant during the program or within 90 days after the last dose
• Patient is an unsterilized male who is sexually active while participating in the program and does not intend to use effective methods of contraception during the program through 90 days after the last dose or plans to donate sperm during the program or through 90 days after the last dose.
• The patient has previously received rituximab, and the last rituximab dose was received less than 6 months before the first dose of efgartigimod

Contacts and Locations

Locations

United States, Illinois

Investigator site 12 - Approved for Marketing

Chicago, Illinois, United States, 60611

United States, Kentucky

Investigator site 16 - Approved for Marketing

Lexington, Kentucky, United States, 40506

United States, Michigan

Investigator site 1 - Approved for Marketing

Ann Arbor, Michigan, United States, 41809

United States, New York

Investigator Site 6 - Approved for Marketing

New Hyde Park, New York, United States, 11042

United States, Pennsylvania

Investigator site 14 - Approved for Marketing

Philadelphia, Pennsylvania, United States, 19104

United States, Virginia

Investigator site 2 - Approved for Marketing

Henrico, Virginia, United States, 23233

Sponsors and Collaborators

argenx

More Information

• Responsible Party: argenx
• ClinicalTrials.gov Identifier: NCT04777734
• Other Study ID Numbers: ARGX-113-EAP-2101
• First Posted: March 2, 2021
• Last Update Posted: April 29, 2022
• Last Verified: April 2022

Additional relevant MeSH terms:

Myasthenia Gravis; Muscle Weakness; Muscular Diseases; Musculoskeletal Diseases; Neuromuscular Manifestations; Neurologic Manifestations; Nervous System Diseases; Pathologic Processes; Paraneoplastic Syndromes, Nervous System; Nervous System Neoplasms; Neoplasms by Site; Neoplasms; Paraneoplastic Syndromes; Autoimmune Diseases of the Nervous System; Neurodegenerative Diseases; Neuromuscular Junction Diseases; Neuromuscular Diseases; Autoimmune Diseases; Immune System Diseases